Latent viruses in human genome

Latent viruses in human genome inspire novel directions for kidney cancer immunotherapy

Dana-Farber investigators found that normally defunct viral genes that lie dormant in the human genome can be activated in the most common form of kidney cancer (clear cell renal cell carcinoma) and can end up triggering an immune response against the cancer. The human genome contains viral DNA that was integrated into the genomic code long ago. A subset of these viral genes can still be reactivated under certain circumstances to produce viral proteins.

Published in Cell, this study showed that when the tumor suppressor gene VHL is inactivated by a mutation—a hallmark of clear cell renal cell cancer cells—these viruses in our genome (called endogenous retroviruses) are more likely to produce their proteins and that this process is driven by a human protein called HIF2, which is overabundant when VHL is crippled.

The team also found that the cancer cells break these viral proteins into fragments and present them on the cell surface as flags that have the potential to stimulate an immune response. Additional tests in human samples and in mice suggest that these flags can be detected by the immune cells called T cells and do stimulate an immune response against the cancer.

Evidence suggests that kidney cancer, unlike most other forms of cancer, is sometimes eradicated by the immune system. Exactly how is not well understood. This study suggests that the immune system can mount an attack on cancer cells that, due to the presence of cancer-driving mutations, present fragments of endogenous retroviral proteins on their surface. The discovery points to the potential for investigating new ways to leverage endogenous retroviruses in the development of novel immunotherapies.

Kidney cancer, renal cell carcinoma, tumor growth, nephrectomy, targeted therapy, immunotherapy, metastatic kidney cancer, oncogenes, tumor microenvironment, angiogenesis, renal biopsy, VEGF inhibitors, checkpoint inhibitors, genetic mutations, risk factors, early detection, survival rates, kidney cancer symptoms, renal oncology, clinical trials

#KidneyCancer, #RenalCellCarcinoma, #TumorGrowth, #Nephrectomy, #TargetedTherapy, #Immunotherapy, #MetastaticCancer, #Oncogenes, #TumorMicroenvironment, #Angiogenesis, #RenalBiopsy, #VEGFinhibitors, #CheckpointInhibitors, #GeneticMutations, #CancerRiskFactors, #EarlyDetection, #SurvivalRates, #CancerSymptoms, #RenalOncology, #ClinicalTrials

International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare